UK Markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.10+0.65 (+8.72%)
As of 01:47PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.45
Open8.02
Bid0.00 x 0
Ask0.00 x 0
Day's range8.02 - 8.10
52-week range5.59 - 9.25
Volume1,305
Avg. volume330
Market cap746.204M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-0.55
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Silence Therapeutics Begins Exclusive Nasdaq Trading

    Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the “Ordinary Shares”) to trading on AIM (the “AIM Delisting”) was e

  • Globe Newswire

    Silence Therapeutics to Present at Jefferies London Healthcare Conference

    Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021. The on-dema

  • Globe Newswire

    Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

    Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that a leading healthcare focused investment firm, Frazier Life Sciences Public Fund, purchased approximately $20 millio